Scarica l'app Stockscreener
23.42
3.50%
-0.85
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DYN Giù?
Forum
Previsione
Dyne Therapeutics Inc Borsa (DYN) Ultime notizie
A Quick Look at Today's Ratings for Dyne Therapeutics(DYN.US), With a Forecast Between $30 to $47 - Moomoo
Dyne Therapeutics(DYN.US) Director Sells US$17.86 Million in Common Stock - Moomoo
Form 4 Dyne Therapeutics Inc For: 8 July By Investing.com - Investing.com Nigeria
Dyne therapeutics director Jason Rhodes sells $17.86 million in stock - Investing.com
Dyne Therapeutics (DYN) director-linked Atlas funds sell 777K shares under 10b5-1 plan - Stock Titan
Myotonic Dystrophy Market Expected to Experience Accelerated Growth and Market Evolution by 2036 – DelveInsight | Design Therapeutics, Enzerna, Juvena Therapeutics, Dyne Therapeutics, Avidity Bioscien - Barchart.com
Form 144 Dyne Therapeutics For: 7 July By Investing.com - Investing.com India
[144] Dyne Therapeutics, Inc. SEC Filing - Stock Titan
(DYN) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Dyne Therapeutics (DYN) Surges Over 5% as Momentum Builds Above Key SupportRSI Oversold Picks - dars.gov.et
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026? - The Motley Fool
DYN Stock Price | Analyst Target 42.43 & Strong Buy Consensus - eToro
Price to book forward of Dyne Therapeutics, Inc. – NASDAQ:DYN - TradingView
DYNE THERAPEUTICS INC (DYN) Stock Chart - ChartMill
Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026? - The Motley Fool
Dyne therapeutics director Jason Rhodes sells $10.7m in stock - Investing.com UK
Dyne therapeutics director Jason Rhodes sells $10.7m in stock By Investing.com - Investing.com South Africa
Form 4 Dyne Therapeutics Inc For: 30 June By Investing.com - Investing.com South Africa
Dyne Therapeutics(DYN.US) Director Sells US$10.71 Million in Common Stock - Moomoo
Atlas funds linked to Dyne (DYN) director sell 504,695 shares - Stock Titan
Myotonic Dystrophy Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Dyne Therapeutics, Avidity Biosciences, Harmony Biosciences, AMO Pharma, Lupin, AMO Pharma - Barchart.com
Form 144 Dyne Therapeutics For: 29 June By Investing.com - Investing.com Nigeria
Bronstein, Gewirtz & Grossman, LLC Encourages Dyne Therapeutics - The National Law Review
Form 144 Dyne Therapeutics For: 26 June By Investing.com - Investing.com Nigeria
Price to sales forward of Dyne Therapeutics, Inc. – NASDAQ:DYN - TradingView
DYN Initiated Coverage by TD Cowen -- Rating Set to Buy - GuruFocus
Enterprise value to EBIT forward of Dyne Therapeutics Inc – BX:DYN - TradingView
Dyne therapeutics director Jason P Rhodes sells $5.65m in stock - Investing.com UK
Price to earnings forward of Dyne Therapeutics, Inc. – NASDAQ:DYN - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Price to earnings forward of Dyne Therapeutics Inc – BX:DYN - TradingView
Form 4 Dyne Therapeutics Inc For: 26 June By Investing.com - Investing.com Australia
Enterprise value to revenue forward of Dyne Therapeutics Inc – BX:DYN - TradingView
Dyne Therapeutics (NASDAQ: DYN) CFO sells 2,362 shares to cover taxes - Stock Titan
Dyne Therapeutics(DYN.US) Director Sells US$5.65 Million in Common Stock - Moomoo
Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Dyne Therapeutics Insider Sold Shares Worth $5,646,497, According to a Recent SEC Filing - marketscreener.com
TD Cowen Initiates Dyne Therapeutics at Buy - Moomoo
TD Cowen Initiates Dyne Therapeutics(DYN.US) With Buy Rating - Moomoo
Dyne Therapeutics stock initiated at buy by TD Cowen on platform - Investing.com UK
Dyne Therapeutics stock initiated at buy by TD Cowen on platform By Investing.com - Investing.com Australia
Dyne Therapeutics (DYN) director-linked funds sell 267,760 shares - Stock Titan
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):